Precision prognostication in neuroblastomas via clinically validated E2F activity signatures
The E2F-related prognostic signature effectively stratifies NB patients by risk and provides potential biomarkers for prognosis and targeted therapy in HR-NB patients. The identified signature enhances patient stratification and provides insights into NB tumor biology, the immune landscape, and potential treatment strategies.
Authors
- Xu Di (ORCID: https://orcid.org/0000-0002-4556-0349)
- De Cai (ORCID: https://orcid.org/0000-0002-9568-5318)
- Shiwei He (ORCID: https://orcid.org/0000-0002-9552-4389)
- Lizhi Li (ORCID: https://orcid.org/0000-0002-3957-1025)
- Huihuang Xu
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1612667
- Citations
- 2
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.78